SAFE-D Study

Full title: Surveillance of pAncreatic health aFter diabEtes Diagnosis

This is a randomised trial to evaluate the cfDNA Pancreatic Cancer test (Avantect) in the early detection of pancreatic cancer in patients with newly diagnosed diabetes mellitus.

Who is eligible to take part?
You are eligible if you have been diagnosed with type 2 diabetes in the past 6 months and aged between 50 to 84 yrs.

Pancreatic cancer is damages insulin producing cells similar to diabetes. So people diagnosed with diabetes have a higher chance who being diagnosed with pancreatic cancer. Currently there is no screening test for pancreatic cancer. This new Avantect test is designed to detect the possible presence of pancreatic cancer at an early treatable stage, long before symptoms become apparent.

If you are interested in more information, the study website goes deeper the what is involved in the study and if you think you are eligible, you can express your interest there.

Study Website: https://safe-d.uk/